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A rare case of Bowen’s disease (BD) in a patient with Primary Sjo¨gren’s syndrome is reported. A 42-year-old woman suﬀering from
Primary Sjo¨gren’s syndrome retained on the basis of clinical and serological ﬁndings, was admitted 3 years later for genital bleeding. The
diagnosis of Bowen’s disease was established by clinical and histolopathological examination. Classical association of lymphoma and
Sjo¨gren’s syndrome is described, but to the best of our knowledge, it is the second report of BD associated to Sjo¨gren’s syndrome in
published literature. A common physio-pathological etiology cannot be excluded.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Bowen’s disease (BD) or squamous cell carcinoma
in situ of the skin, is a malignant neoplasm restricted to
the epidermis, without evidence of dermal invasion
(Bowen, 1912). It was ﬁrst described by Bowen in 1912
(Bowen, 1912). Major etiological factors for this disease
are UV light, human papillomavirus infection and immu-
nosuppression (Arlette and Trotter, 2004). The association
of Sjo¨gren’s syndrome with lymphoma is well documented
as in approximately 5% of patients (Kassan et al., 1978).http://dx.doi.org/10.1016/j.jdds.2014.05.002
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patient with Sjo¨gren’s syndrome was reported once in pub-
lished literature (Lazarus and Robinson, 2006).
We report a case of Bowen’s disease in a 42 year old
patient with Primary Sjo¨gren’s syndrome.2. Case report
A 42-year-old female, was referred in 2006 for genital
bleeding.
In her past medical history, she was admitted in our
department 3 years ago for dryness of the mouth and eyes.
Physical examination revealed only unilateral conjunctival
hyperhemia and mild dryness over the oral mucosa. There
was no hepatomegaly, no splenomegaly, no parotid hyper-
trophia, nor lymph nodes. Cardiopulmonary and neuro-
logical examinations were normal. On ophthalmological
exam, ocular dryness was objectively assessed. Laboratory
data revealed a polyclonal hyperglobulinemia (28.4 g/l) onSaud University.
commons.org/licenses/by-nc-nd/3.0/).
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Albuminemia were within reference limits. The white blood
cell count was 9900/mm3 without lymphopenia and hemo-
globin level was 12 g/dL. Inﬂammatory indices, erythro-
cyte sedimentation rate and C-reactive protein were
increased. Serum creatinine was 73 umol/L (creatinine
clearance 60 mL/min). Her liver function was normal. Posi-
tive anti-SSA/anti-SSB autoantibodies were subsequently
found. A chest X-ray was without abnormalities. Anato-
mo-pathological examination of salivary glands biopsy
showed lymphocytic sialadenitis grade III. Sjo¨gren’s syn-
drome (SS) was diagnosed according to the new classiﬁca-
tion criteria for SS (SICCA Group 2012). The diagnosis of
Primary SS was retained after eliminating other auto-
immune and connective tissue diseases.
She was suﬀering from genital bleeding since 4 days (see
Fig. 1). Physical examination revealed marked cervicitis
with bleeding in contact and vulvar lesions. Partial vulvec-
tomy was performed and the histological ﬁnding was a vul-
var intraepithelial neoplasia. Serologic tests for hepatitis B
and C, human immunodeﬁciency virus (HIV), syphilis and
chlamydiae were negative. A hysterectomy with oophorec-
tomy was completed and histopathological examination
showed inﬂammatory transformations, metaplasia without
signs of human papillomavirus infection or intraepithelial
transformations. Postoperative search for metastasis
including computed tomography scan of the abdomen, pel-Figure 1. Pigmented papules 0.5–1 cm in diameter based on an erythem-
atous and hypochromic skin at the perianal region and the minora labia.vis and chest, mammography and bone scintigraphy, were
without abnormalities.
In 2012, she was admitted for rectal bleeding. She denied
any abdominal pain, bowel disorders or weight loss. On
physical examination, there was no splenomegaly, no
lymph nodes nor parotid hypertrophia with a normal level
of Beta 2 microglobulin. Chest tomography scan did not
show any mediastinal lymph nodes. Coloscopy and rectos-
copy were performed. Histopathologic examination
showed anal and perianal locations of Bowen’s disease. A
surgical treatment was proposed but refused by the patient
in view of high risks of sequellae. She was treated in the
dermatology department by laser CO2 therapy with a good
initial outcome.
3. Discussion
Bowen’s disease (BD), a form of squamous cell carci-
noma in situ, represents an early stage cutaneous malignant
neoplasm. It usually presents as a well-deﬁned erythema-
tous plaque (Kiran Attili and Ibbotson, 2009). Although
the etiology of BD is unclear, it is most commonly associ-
ated with chronic sun exposure. Other possible etiologies
include exposure to arsenic, immunosuppression, chronic
inﬂammatory processes or scarring, and human papilloma-
virus, particularly in acral and genital locations (Arlette
and Trotter, 2004). Lesions are common on the head and
neck and lower limbs, although any site can be involved.
A delay in diagnosis is often encountered because the lesion
is asymptomatic. Histological conﬁrmation might therefore
be necessary when clinical diﬀerentiation between these dis-
eases is diﬃcult (Kiran Attili and Ibbotson, 2009).
Cancer has long been associated with systemic autoim-
mune diseases (Bernatsky et al., 2005; Rosenthal et al.,
1993). The high incidence of lymphoma in Primary Sjo¨-
gren’s syndrome (SS) was ﬁrst reported in 1963 by Bunim
and Talal (Voulgarelis et al., 2001) and has been veriﬁed
in several studies since (Kassan et al., 1978; Lazarus and
Robinson, 2006; Kiran Attili and Ibbotson, 2009;
Bernatsky et al., 2005; Rosenthal et al., 1993; Voulgarelis
et al., 2001; Zuﬀery et al., 1995). The incidence of non-
Hodgkin’s lymphoma is higher in SS than in other autoim-
mune diseases rendering this research model more than
ideal in investigating the relationship between autoimmu-
nity and lymphomagenesis (Smedby et al., 2006). More
speciﬁcally, according to a meta-analysis of 20 studies with
diﬀerent autoimmune diseases, aiming to evaluate the risk
of lymphoma development, SS correlates with high risk
for lymphoma development with a standardized incidence
rate (SIR) of 18.8% compared to moderate risk for sys-
temic lupus erythematosus (SIR 7.5%) and low risk for
rheumatoid arthritis (SIR 3.3%) (Zintzaras et al., 2005).
It is believed that chronic antigenic stimulation, observed
since the early stages of SS, triggers the mechanism of poly-
clonal B-cell activation. This, in turn, is responsible for the
production of B-lymphocyte clones capable of inducing
neoplasia (Voulgarelis and Moutsopoulos, 2003). In this
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is associated with many parameters such as chronic hypo-
complementemia, mixed monoclonal cryoglobulinemia,
lymphocytopenia, palpable purpura, swollen salivary
glands, lymphadenopathy, splenomegaly, and peripheral
neuropathy (Loannidis et al., 2002).
There have been case reports of other cancers, including
solid organ tumours, also occurring in patients with SS
(Ota et al., 1995; Takabatake et al., 1999). However,
according to published literature, no study has fully inves-
tigated the incidence of non-lymphoid cancers in SS. A ret-
rospective analysis documenting the incidence of all
malignancies in a cohort of 112 patients with SS (six males,
106 females) and comparing it with the incidence in the
general population, conﬁrmed that patients with SS have
an increased risk of developing lymphomas (Lazarus and
Robinson, 2006). Malignancies occurred in 25 patients.
Lymphoma was present in 11 cases. Nine patients (8%)
developed two malignancies. Of the 11 patients with lym-
phoma, ﬁve developed additional cancers; The incidence
was calculated as being 37.5 times than that in the general
population (Bowen, 1912), similar to previous studies,
which have calculated relative risks between 33 and 44 in
populations of similar age, race and sex (Kassan et al.,
1978; Voulgarelis et al., 2001). The overall incidence of
all cancers was 2.6 times than that in the general popula-
tion, but this was almost entirely due to the excess occur-
rence of lymphoma. The SIR for non-lymphoid
malignancy was 1.5, but this was based on a small number
of excess cases and was not statistically signiﬁcant. A recent
meta-analysis of fourteen studies involving more than 14
523 patients with SS, indicated that SS is signiﬁcantly asso-
ciated with increased risks of overall malignancy, non
hodgkinian lymphoma and thyroid cancer (Liang et al.,
2013). However, it is not yet known whether the apparent
increased risk of overall malignancy in patients with SS is
due to the relatively high prevalence of non hodgkinian
lymphoma in that group (Liang et al., 2013).
The prevalence of SS in general population is esti-
mated between 0.6% and 1.7% (Martel et al., in press).
There are no reliable estimates of the prevalence of
Bowen’s disease in the general population Clinical recog-
nition of Bowen’s disease can be subject to a high degree
of error, even among dermatologists, which would ham-
per studies without biopsy conﬁrmation of the clinical
diagnosis. Authors from Australia were able to analyze
1001 biopsy specimen obtained during 3 year period
(Kossard and Rosen, 1992). This can be contrasted with
the 40-year period required to accumulate 617 cases in
a study of Bowen’s disease from Denmark (Thestrup-
Pedersen et al., 1988). In our knowledge and according
to published literature, an only case of an association Sjo¨-
gren’s and Bowen’s disease was reported (Lazarus and
Robinson, 2006). The diagnosis of Bowen’s disease of
the skin was established in a female patient aged 74 years,
3 years before diagnosing SS and 9 years before discover-
ing lung carcinoma (Lazarus and Robinson, 2006). Ourcase is second. The increase in the incidence of cancers
was not proven but the observation that some patients
developed more than one cancer raises the possibility that
there may be a subgroup of patients who are at greater
risk of developing cancer. Although, the association of
Bowen’s disease to a Sjogren’s syndrome is rare and
can be just a chance association, a common physio-path-
ological etiology cannot be excluded. We propose the
hypothesis of pathogenic factors that may be involved
in the development of lymphoma (Fox et al., 1989;
Klussmann et al., 2003; Masaki and Sugai, 2004), includ-
ing a number of oncogenes, cell surface molecules and
viruses that can be involved in the development of
Bowen’s disease. Immunosuppressant/cytotoxic medica-
tions could also possibly have a role in causing additional
cancers. Large multicentre studies investigating the inci-
dence of malignancy specially Bowen’s disease, in patients
with Sjogren’s syndrome should be made to try to ﬁnd a
connection and explanation for this occurrence.
4. Conclusion
In our knowledge, we report the second case in pub-
lished literature of an association between Primary Sjo¨-
gren’s syndrome and Bowen’ disease.
This suggests the existence of pathogenic ﬁliation. We
propose the hypothesis of pathogenic role of viral and/or
oncogenic agents in the development of carcinomatous
lesions.
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